For some medical conditions there are hundreds of bacteria shifts reported, for others only a few. The Percentage is based on the least number. If there are matches 8 matches for a condition that has 10 known bacteria shifts, against a condition that has 50 bacteria shifts. It will be 8/10 or 80% and not 8/50= 16%. The count of possible bacteria is shown for reference.
Limited to conditions with 5 or more bacteria
Name | Overlap Percent | Prevalance in Population | Matches | Bacteria in From | Bacteria in To |
---|---|---|---|---|---|
Allergies | 26 % | 30% | 13 | 50 | 110 |
Ankylosing spondylitis | 35.5 % | 7% | 39 | 520 | 110 |
Alzheimer's disease | 40 % | 10% | 20 | 50 | 110 |
Ulcerative colitis | 25 % | 0.1% | 27 | 108 | 110 |
Rosacea | 45.5 % | 5.46% | 10 | 22 | 110 |
Schizophrenia | 31.2 % | 0.75% | 29 | 93 | 110 |
Multiple Sclerosis | 31 % | 0.5% | 31 | 100 | 110 |
Mood Disorders | 33.3 % | 29.7% | 2 | 6 | 110 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 31.8 % | 0.86% | 35 | 134 | 110 |
Psoriasis | 41.3 % | 3% | 19 | 46 | 110 |
Obesity | 32.7 % | 42.4% | 18 | 55 | 110 |
Obesity | 21.2 % | 42.4% | 22 | 104 | 110 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 39.5 % | 0.005% | 17 | 43 | 110 |
Osteoporosis | 40.9 % | 9.4% | 9 | 22 | 110 |
neuropsychiatric disorders (PANDAS, PANS) | 46.7 % | 0.1% | 7 | 15 | 110 |
ME/CFS with IBS | 31.6 % | 2.8% | 6 | 19 | 110 |
ME/CFS without IBS | 19.2 % | 0.4% | 5 | 26 | 110 |
Multiple system atrophy (MSA) | 28.6 % | 0.005% | 6 | 21 | 110 |
Metabolic Syndrome | 42.9 % | 21% | 3 | 7 | 110 |
Systemic Lupus Erythematosus | 31.8 % | 0.15% | 21 | 66 | 110 |
Liver Cirrhosis | 52.7 % | 0.27% | 58 | 678 | 110 |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 28.9 % | 25% | 22 | 76 | 110 |
Parkinson's Disease | 31.1 % | 1% | 28 | 90 | 110 |
Chronic Kidney Disease | 45.7 % | 15% | 16 | 35 | 110 |
Insomnia | 40 % | 30% | 4 | 10 | 110 |
Depression | 33.3 % | 8% | 27 | 81 | 110 |
Irritable Bowel Syndrome | 32.3 % | 15% | 20 | 62 | 110 |
Chronic Urticaria (Hives) | 39.1 % | 5% | 9 | 23 | 110 |
IgA nephropathy (IgAN) | 41.4 % | 0.001% | 12 | 29 | 110 |
Hyperlipidemia (High Blood Fats) | 24 % | 33% | 6 | 25 | 110 |
hypertension (High Blood Pressure | 50 % | 47% | 3 | 6 | 110 |
hypercholesterolemia (High Cholesterol) | 44.4 % | 12% | 4 | 9 | 110 |
Allergic Rhinitis (Hay Fever) | 22.2 % | 7.8% | 8 | 36 | 110 |
gallstone disease (gsd) | 66.7 % | 5% | 10 | 15 | 110 |
Graves' disease | 37.5 % | 0.5% | 3 | 8 | 110 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 25 % | 27.8% | 6 | 24 | 110 |
Fibromyalgia | 43.2 % | 1.12% | 16 | 37 | 110 |
Functional constipation / chronic idiopathic constipation | 43.9 % | 14% | 18 | 41 | 110 |
Type 1 Diabetes | 32.7 % | 0.19% | 17 | 52 | 110 |
Gout | 19 % | 6.8% | 4 | 21 | 110 |
Epilepsy | 36 % | 0.84% | 9 | 25 | 110 |
Cerebral Palsy | 58.8 % | 0.2% | 10 | 17 | 110 |
Inflammatory Bowel Disease | 40.9 % | 1.3% | 27 | 66 | 110 |
Celiac Disease | 35.8 % | 1.4% | 24 | 67 | 110 |
COVID-19 | 16.7 % | 50% | 6 | 36 | 110 |
Carcinoma | 35.3 % | 1% | 18 | 51 | 110 |
Bipolar Disorder | 36.4 % | 3% | 12 | 33 | 110 |
Colorectal Cancer | 22.7 % | 4.3% | 25 | 296 | 110 |
Chronic Fatigue Syndrome | 29.1 % | 3% | 16 | 55 | 110 |
Coronary artery disease | 37.5 % | 6.7% | 6 | 16 | 110 |
Crohn's Disease | 40 % | 0.3% | 44 | 141 | 110 |
Barrett esophagus cancer | 31.3 % | 7% | 5 | 16 | 110 |
Generalized anxiety disorder | 21.4 % | 2.7% | 3 | 14 | 110 |
Asthma | 33.3 % | 8% | 9 | 27 | 110 |
Atherosclerosis | 38.2 % | 50% | 42 | 524 | 110 |
Acne | 36.8 % | 47% | 7 | 19 | 110 |
Stress / posttraumatic stress disorder | 37.5 % | 5.2% | 21 | 56 | 110 |
Small Intestinal Bacterial Overgrowth (SIBO) | 25 % | 52% | 4 | 16 | 110 |
Brain Trauma | 59.1 % | 0.367% | 13 | 22 | 110 |
Sjögren syndrome | 43.9 % | 1.2% | 18 | 41 | 110 |
Type 2 Diabetes | 55.5 % | 10.8% | 61 | 267 | 110 |
ADHD | 31.9 % | 9.4% | 15 | 47 | 110 |
Hashimoto's thyroiditis | 50 % | 0.35% | 7 | 14 | 110 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Copyright 2016-2023 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 ยงโฏ1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.